Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

Study:

A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Coronary Artery Bypass (OPCAB) Surgery

Rationale:

n/a

Purpose:

The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cardiac Surgery
Coronary Artery Bypass Surgery
Drug: Bivalirudin
Drug: Heparin
Drug: Protamine
Phase 3

Verified by The Medicines Company November, 2011

Sponsored by: The Medicines Company
Information provided by: The Medicines Company
ClinicalTrials.gov identifier: NCT00073593

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Andrew Sternlicht, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site